Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.

ABSTRACT:

Aims

Sacubitril/valsartan is a neprilysin-inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post-hoc analysis of a 3-year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in patients with heart failure and type 2 diabetes. We previously reported that sacubitril/valsartan combined with a dipeptidyl peptidase-4 inhibitor increases active glucagon-like peptide-1 (GLP-1) in healthy individuals. We now hypothesized that administration of sacubitril/valsartan with or without a dipeptidyl peptidase-4 inhibitor would lower postprandial glucose concentrations (primary outcome) in patients with type 2 diabetes via increased active GLP-1.

Methods

We performed a crossover trial in 12 patients with obesit

SUBMITTER: Wewer Albrechtsen NJ 

PROVIDER: S-EPMC9545540 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature